搜索
Search
img

News Center

新闻中心

Kintor Pharmaceutical Releases the Final Data of Proxalutamide in the Treatment of Male Subjects Infected with COVID-19

  • Time of issue:2021-01-07

(Summary description)Suzhou, Jan 10, 2021--Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to announce that the final trial results of Proxalutamide for the treatment of male subjects infected with COVID-19 in Brazil were released. The results showed that Proxalutamide could significantly inhibit the transition of condition of subjects infected with COVID-19 from mild to severe and had good safety for short-term administration (15 days).

Kintor Pharmaceutical Releases the Final Data of Proxalutamide in the Treatment of Male Subjects Infected with COVID-19

(Summary description)Suzhou, Jan 10, 2021--Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to announce that the final trial results of Proxalutamide for the treatment of male subjects infected with COVID-19 in Brazil were released. The results showed that Proxalutamide could significantly inhibit the transition of condition of subjects infected with COVID-19 from mild to severe and had good safety for short-term administration (15 days).

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2021-01-07 16:56
  • Views:
Information

Suzhou, Jan 10, 2021--Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to announce that the final trial results of Proxalutamide for the treatment of male subjects infected with COVID-19 in Brazil were released. The results showed that Proxalutamide could significantly inhibit the transition of condition of subjects infected with COVID-19 from mild to severe and had good safety for short-term administration (15 days).

 

The clinical trial of Proxalutamide in the treatment of COVID-19 (NCT04446429) is a randomised, double-blind and placebo-controlled clinical trial, designed to explore the effectiveness of Proxalutamide in the treatment of COVID-19, and with an aim to accelerate the turning from positive to negative and prevent the transition from mild to severe by inhibiting the replication and reproduction of the virus. The primary endpoints include the percentage of subjects hospitalized for the COVID-19 within 30 days and the evaluation of clinical symptoms.

 

The final results of clinical trial included data of 134 subjects in the Proxalutamide Arm and 128 subjects in the Controlled Arm with placebo, which showed that no subjects were hospitalised in the Proxalutamide Arm, and the hospitalisation rate was 0%; as compared to 35 subjects were hospitalised in the Controlled Arm due to the worsening of the condition and the hospitalisation rate was 27%. Proxalutamide could significantly reduce the hospitalisation rate of subjects infected with COVID-19 and no adverse events related to Proxalutamide were observed during the study period.

 

(In the preliminary data of the clinical trial of Proxalutamide in the treatment of COVID-19 published by Kintor Pharmaceutical on 11 December 2020, one subject in the Proxalutamide Arm was hospitalised for treatment, which was an information error and was corrected.)

 

Detailed final clinical trial data can be obtained through the papers planned to be published in the near future.

 

In addition, a clinical trial of Proxalutamide in the treatment of female subjects infected with COVID-19 is currently carried out in Brazil with an aim to enroll a total of 168 subjects. The preliminary data will also be released in the near future. Please stay tuned.

 

Dr. Tong Youzhi, the founder, Chairman and CEO of Kintor Pharmaceutical indicated, “We are pleased to see that Proxalutamide has an excellent performance in the treatment of COVID-19. Recently, the epidemic in some areas has become more and more serious, and mutated new coronavirus has appeared in many countries, which has accelerated the spread of the epidemic. We will accelerate the international multi-center phase III clinical trial of Proxalutamide in the treatment of COVID-19, so as to benefit more COVID-19 patients as soon as possible.”

Scan the QR code to read on your phone